Document is current
Any future updates will be listed below
-
Authors
Song, Yun-Jeong
Choi, In Ah.
Meylan, Françoise
Demoruelle, M. Kristen
Farley, Taylor
Richard, Arianne C.
Hawley, Eric
Botson, John
Hong, Yoo Jin
Lee, Eun Young
Mian, Sabina R.
Hamilton, Bartlett C.
Thiele, Geoffrey M.
Mikuls, Ted R.
Gara, Naveen
Ward, Chris D.
Lamberth, Sarah
Deane, Kevin D.
Heller, Theo
Ward, Michael M.
Lee, David M.
Migone, Thi-Sau
Stohl, William
O’Dell, James R.
Norris, Jill M.
Holers, V. Michael
Gregersen, Peter
Song, Yeong-Wook
Siegel, Richard M. http://orcid.org/0000-0001-5953-9893
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (Intramural, AR066712)
National Institute of Allergy and Infectious Diseases (AI101981)
Ministry of Science, ICT and Future Planning (NRF-2015M3A9B6052011)
- License Information
-
More Information
Article History
Received: 5 October 2019
Accepted: 23 April 2020
First Online: 7 May 2020
Ethics approval and consent to participate
: All animal studies were approved by the NIAMS Animal Care and Use Committee. All subjects provided informed consent and sample collection and sharing was approved by the local IRB. All authors provided input on the paper and consent for publication.
: Not applicable
: Chris D. Ward and Thi-Sau Migone were employees of Human Genome Sciences and owners of HGSI stock. Sarah Lamberth and David Lee are employees of Janssen Pharmaceuticals and own stock. V. Michael Holers and Kevin D. Deane are co-holders of a Stanford University patent on use of biomarkers to predict RA development. Richard Siegel, Yun-Jeong Song, and Françoise Meylan hold a patent on anti-TL1A antibodies. Richard Siegel has been an employee of Novartis Institutes of Biomedical Research since 2018 and owns Novartis stock. The remaining authors declared no conflict of interest.
